Saffron Extract for Mood: What Human Trials Actually Show

What the evidence shows

Randomized trials suggest a possible short-term reduction in depressive symptoms, but results are not uniformly positive.
Earlier studies were often small, short, and concentrated in adults with mild-to-moderate depression, mostly in Iran.
A 2025 trial in 202 adults with subclinical depressive symptoms found a modest primary-outcome benefit after 12 weeks.
A separate 2025 study in 51 healthy adults with subclinical symptoms found no significant improvement in its primary depression-related outcomes.
Meta-analyses report favorable average effects but also identify publication bias, inconsistent outcome measures, and limited regional diversity.
The evidence does not establish long-term benefit, broad safety, product interchangeability, or equivalence to antidepressant medication.

The short answer

Human research shows a recurring signal that saffron extract can improve depressive-symptom scores compared with placebo, but the signal is not consistent enough to establish a dependable effect for every population or product.

Earlier randomized trials generally studied adults with mild-to-moderate depression or clinically significant depressive symptoms. They were usually double-blind, placebo-controlled or compared saffron with an antidepressant, and lasted roughly six to eight weeks. These designs are useful for testing short-term symptom change, but they do not establish long-term benefits, relapse prevention, or effects in severe depression.

The newer evidence is more mixed. A 2025 trial in 202 adults with subclinical depressive symptoms reported a modest advantage on its primary depression measure after 12 weeks, while another 2025 placebo-controlled study in 51 healthy adults with subclinical symptoms found no significant improvement in its primary composite measure or individual depressive-symptom scores.

The most defensible interpretation is that saffron extracts are a promising but still uncertain research intervention for short-term mood symptoms. The evidence does not show that saffron prevents depression, replaces established care, or works equally well across standardized extracts and populations.

What the earlier randomized trials studied

The earliest clinical evidence came mainly from small Iranian trials involving adults with depressive symptoms or mild-to-moderate depression. The studies summarized in an open-access meta-analysis used randomized, double-blind designs and compared saffron preparations with placebo, imipramine, or fluoxetine. Several trials used formal depression assessments, and some enrolled participants who met structured criteria for major depressive disorder.

The placebo-controlled studies reported greater reductions in depression scores with saffron than with placebo. Trials comparing saffron with fluoxetine or imipramine reported improvement in both groups without a statistically clear difference between them. That pattern is compatible with a possible antidepressant signal, but it should not be described as proof that saffron is equivalent to prescription medication. A failure to detect a difference in a small trial is not the same as demonstrating equivalence.

The main design strengths were randomization, blinding, use of active comparators in some studies, and validated symptom scales. The main weaknesses were limited sample sizes, short follow-up, concentration of research in one region, and repeated testing of closely related saffron preparations. These factors make the findings vulnerable to chance, expectancy effects, and limited generalizability.

Why the meta-analyses look encouraging

Systematic reviews generally find a favorable average result, but their conclusions depend heavily on which trials and outcome measures are combined. A 2019 review included 23 randomized studies across clinical and general populations and reported a large average effect against placebo for depressive symptoms. The authors also identified evidence of publication bias and limited regional diversity, both of which reduce confidence in the apparent size of the benefit.

A separate review focused more narrowly on mild-to-moderate depression and found saffron favored placebo while showing no statistically clear difference from tested antidepressants. Again, that result indicates a signal in the available trials; it does not prove that all saffron products perform alike or that saffron has the same clinical value as standard medication.

An umbrella review published in 2022 illustrates the uncertainty. It found a significant improvement when studies using the Beck Depression Inventory were pooled, but did not find clear improvement when Hamilton Depression Rating Scale results or mixed depression scales were combined. Differences between scales, populations, extract formulations, and study quality can therefore change the overall conclusion.

Meta-analyses increase statistical power, but they cannot remove weaknesses shared by the underlying trials.
A large standardized effect can be exaggerated when studies are small, short, geographically concentrated, or selectively published.
Agreement across several reviews is meaningful, but disagreement across outcome measures argues for cautious interpretation.

What newer low-mood studies add

The 2025 randomized, double-blind, placebo-controlled trial of 202 adults aged 18 to 70 examined a branded saffron extract in people with subclinical depressive symptoms rather than a clearly diagnosed major depressive episode. After 12 weeks, the saffron group had a greater improvement on the depression component of the Depression, Anxiety, and Stress Scale than placebo, with a reported Cohen’s d of 0.39. The study also reported no serious adverse reactions.

The result is informative because it is larger and longer than many earlier trials, but it remains one study of one commercial formulation. Its other secondary outcomes did not show clear between-group differences, and the investigators noted a large placebo response. The study also disclosed financial and employment relationships involving the research organization and the extract sponsor. Those disclosures do not invalidate the findings, but they are relevant when judging how independently the result has been replicated.

A separate 2025 randomized, double-blind, placebo-controlled trial studied 51 healthy adults with subclinical neuropsychiatric symptoms for six weeks. It found no significant effect on its primary combined measure of depression, anxiety, and fatigue, nor on the individual depressive-symptom measure. This null result matters because it shows that a positive pattern in clinically depressed or low-mood samples does not automatically generalize to healthy adults with milder symptoms.

Together, the newer studies suggest that population and design matter. Saffron may have a measurable effect in some adults with persistent low mood, while the effect may be smaller, absent, or harder to detect in healthy people with subclinical symptoms.

How strong is the evidence?

The evidence is stronger than anecdotal reports because multiple randomized trials have used placebo controls, blinding, and validated mood scales. The repeated direction of some placebo-controlled findings is a legitimate reason for continued research.

However, the overall certainty remains limited. Most studies are short, and many earlier trials are small. The research base has also used different plant parts, extraction methods, chemical standardizations, brands, and outcome scales. Results from one standardized extract cannot automatically be applied to culinary saffron, another supplement, or a preparation with different concentrations of active constituents.

The comparison with antidepressants requires particular care. Active-comparator trials can show whether two groups change over time, but small studies with no significant difference cannot establish equal efficacy, equal safety, or equal suitability. The available trials also do not establish outcomes for severe depression, suicidal thinking, adolescents, pregnancy, or medically complex populations.

Short-term safety findings are somewhat reassuring but incomplete. Reviews have not consistently found more adverse effects than placebo or antidepressants, and the 2025 larger trial reported no serious adverse reactions. Yet trials of a few weeks or months and a few hundred participants cannot reliably detect rare, delayed, or interaction-related harms.

What remains uncertain

Several questions remain open before the evidence can be considered mature.

Which chemical features of a saffron extract are most important for mood outcomes, and how consistently are they present across products?
Are effects maintained beyond the typical six-to-12-week study period?
Do benefits differ between diagnosed depression, mild-to-moderate symptoms, and healthy adults with low mood?
How much of the observed change reflects expectancy and placebo response rather than a specific saffron effect?
Can independent research teams reproduce the newer positive findings using preregistered protocols and clinically meaningful outcomes?
What are the effects when saffron is combined with prescription medicines or used by people with other health conditions?

Future trials would be more informative if they were larger, independently funded, geographically diverse, transparent about extract composition, and designed with longer follow-up. They should also report remission, functioning, quality of life, adverse events, and whether changes are large enough to matter to participants rather than relying only on statistical differences in symptom scales.

For now, the evidence supports describing saffron extract as an investigational option with a plausible short-term mood signal, not as a proven cure, diagnosis tool, or substitute for professional evaluation and established depression care.

Sources

About this article

NootroWorld publishes research summaries, not medical advice. This article describes what studies have and have not established; it does not tell you what to take. Supplements can interact with medication, pregnancy and existing health conditions, and study populations often differ from your own situation. Discuss any personal decision with a qualified healthcare professional.